Original Article

Sevoflurane prevents pulmonary vascular remodeling and right ventricular dysfunction in pulmonary arterial hypertension in rats

Wenqian Zhai1*, Yunfei Li1*, Yongjuan Luo2, Weidong Gao3, Shan Liu4, Jiange Han1, Jie Geng5

Departments of 1Anesthesiology, 2Ultrasonics, 3Cardiology, Tianjin Chest Hospital, Tianjin 300222, China; 4Department of Anesthesiology & Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore 21205, MD, USA; 5Tianjin Cardiovascular Institute, Tianjin Chest Hospital, Tianjin 300051, China. *Equal contributors.

Received January 16, 2021; Accepted August 12, 2021; Epub October 15, 2021; Published October 30, 2021

Abstract: Background: The cardioprotective properties of sevoflurane have been reported in studies of the left ventricle. However, whether this volatile anesthetic would also be beneficial for pulmonary vascular remodeling and associated right ventricular hypertrophy (RVH) remained to be explored. Here, we investigated the potential benefit of sevoflurane to right heart function in experimental pulmonary arterial hypertension (PAH). Methods: Adult Wistar rats received one dose peritoneal injection of monocrotaline (MCT, 60 mg/kg) or the equal volume of normal saline. Two weeks later, rats were treated with sevoflurane or sham exposure. PAH status and cardiac function were assessed by echocardiography weekly, and the body weight (BW) was monitored every week. After 6 weeks of exercise, Fulton’s index calculation, histological observation, IL-6 and TNF-α immunohistochemical analyses, evaluation of MDA, SOD and GSH-Px levels and NF-κB and MAPK active determination were performed in lung and RV tissue samples. Results: MCT induced pulmonary vascular remodeling, RVH, increased Fulton’s index (P<0.01), and right ventricular failure (RVF) in rats. Animals inhaled sevoflurane had an increased cardiac output (P<0.05) and lower incidence of RVF (P<0.05). Also, these animals had a reduced RVedD, RVWTd and PAI (P<0.05), increased PV (P<0.05), reduced wall thickness and vascular wall area of pulmonary small vascular (vascular external diameter 50-150 um) (P<0.01), reduced RV fibrosis, and increased RV cardiomyocyte area (P<0.01). Furthermore, sevoflurane reduced IL-6 and TNF-α expression in lungs and heart (P<0.01), decreased level of MDA (P<0.01) and increased activity of SOD and GSH-Px (P<0.01). In addition, it decreased the activities of NF-κB and MAPK pathways (P<0.01). Conclusion: Sevoflurane reduces pulmonary vascular remodeling and RVH in PAH induced by MCT in rats. This effect is likely due to down-regulation of inflammatory factors IL-6 and TNF-α, reduced level of oxidative stress and the inhibition of NF-κB and MAPK pathways.

Keywords: Pulmonary arterial hypertension (PAH), right ventricular hypertrophy (RVH), right ventricular failure (RVF), sevoflurane

Introduction

Pulmonary arterial hypertension (PAH) is a life-threatening disease characterized by progressive pulmonary vasoconstriction leading to pulmonary vascular remodeling, and causes the right heart hypertrophy leading to right ventricular failure (RVF) eventually. Although the pathophysiology of PAH has been increasingly recognized, its mortality remains high when RVF develops.

Cardioprotective properties of volatile anesthetics, represented by sevoflurane, have been recognized in preclinical and clinical studies. Sevoflurane administrated before and during ischemia-reperfusion (IR) injury in isolated rat hearts improved the recovery of left ventricle (LV) work, an index of IR injury [1]. This finding is consistent with observation from animal models of LV IR injury in vivo, even if the drug was inhaled for only a short duration before ischemia [2]. Moreover, translational clinical studies suggest that there is a reduction in myocardial damage and mortality in patients treated with sevoflurane during cardiac surgery [3-5]. Furthermore, two international consensus con-
Sevoflurane prevents pulmonary arterial hypertension

References had indicated that the administration of volatile anesthetics is one of the important nonsurgical interventions that is associated with survival benefit [6, 7]. Despite the findings that cardioprotective properties of inhaled anesthetics have been reported in the left heart, there has been little scientific evidence on the beneficial effects of sevoflurane in the right heart.

Inflammation, or more specifically, altered immune process and failure to resolve inflammation, is a compelling signal that causes poor prognosis in PAH patients [8]. Growing studies consistently show that targeting the inflammation could be a potential method to assess and treat right ventricular hypertrophy (RVH) and pulmonary arterial remodeling. Many common signaling molecules, such as NF-κB, MMP-9, TNF-α, IL-6, IL-1, HMGB1, and NLRP3, initiate inflammation response to cause injury. Sevoflurane has been shown to possess anti-inflammation functions. A study described a novel approach to using sevoflurane as a local anti-inflammatory drug, not as an anesthetic, to attenuate inflammatory response both locally and systemically through intramyocardial delivery of sevoflurane in patients undergoing elective mitral valve surgery [9]. Hypothetically, sevoflurane can also prevent pulmonary vascular remodeling and RVH via its anti-inflammation function.

Here, we aimed to investigate the contribution of sevoflurane to pulmonary vascular remodeling and right ventricle (RV) dysfunction in rat model of PAH. In addition, we determined if NF-κB and MAPK pathways are involved in this effect.

**Methods**

**MCT rat model of PAH**

The study was approved by the Ethics Committee of Animal Research of Tianjin Medical University (permission number SYXK(Jin): 2019-0004). Forty-eight clean-grade healthy male adult Wistar rats (Charles River Lab, China), weighting 250-280 g, were used. All animals were raised in constant temperature and humidity with regular light-dark cycle, and had standard chow and tap water ad libitum. One week later, rats were randomly assigned into four groups: Control (group C, n=12), control + sevoflurane group (group CS, n=12), monocrotaline (MCT) group (group M, n=12), and MCT + sevoflurane group (group MS, n=12). In group M and group MS, PAH was induced by an intraperitoneal injection of MCT (CrotalineC2401, 60 mg/kg, Sigma-Aldrich, Buchs, Switzerland), and equal volume of normal saline was injected at the same time in group C and group CS. Diet and activity were monitored closely during the entire course of the experiment for all rats, with the body weight (BW) obtained weekly. All animal care and procedures followed the institutional guideline.

**Administration of sevoflurane**

The rats in group CS and group MS were placed in a sealed resin box and inhaled 1.5 MAC sevoflurane (Abbott, Baar, Switzerland) (mixed with 100% oxygen) input through air inlet using an anesthetic gas evaporator. The concentration of sevoflurane in the box was monitored continuously using a concentration monitor (UltimaTM, Datex/Instrumentarium, Helsinki, Finland), which was connected to air outlet. One hour later, the animal was recovered. Sevoflurane was administered twice a week until 6 weeks for two weeks after MCT injection and the animals in other groups were put in the same environment but did not inhale sevoflurane.

**Echocardiography**

PAH status and cardiac function were confirmed by echocardiography weekly. Before the examination was performed, all rats including control group were anesthetized using 2.5% isoflurane (2:1 ratio of isoflurane: O2). Three electrodes were placed on the three limbs of rats for electrocardiogram variability analysis. Echocardiography was performed using an ultrasound transducer (Philips Ultrasound, Inc., L15-7io, USA), according to previously described methods [10]. After the chest was shaved, the LV end-systolic and end-diastolic volumes were measured from M-mode images (two dimensional) which were obtained from a short axis LV view at the level of the papillary muscles. Then, LV cardiac output (equal to RV cardiac output) was calculated. Cardiac output (ml) = (end-diastolic volume-end systolic volume) × heart rates. The RV end-diastolic dimension (RVEDD), RV wall thickness in diastole (RVWtD), intraventricular septum in diastole (IVSd), and...
LV posterior wall thickness in diastole (LVPWd) were measured from the parasternal long axis LV view. The maximal velocity of pulmonic valve (PV) and pulmonary arterial internal dimension (PAID) were measured from pulmonic valve flow pulse wave Doppler signal obtained at the parasternal short axis LV view. All echocardiographic examinations were performed by the same person at heart rates from 350 to 400 beats/min under anesthesia.

**Evaluation of right ventricular hypertrophy**

After sacrifice of the rats, the thoraxes were opened and the hearts were dissected with atria removed before separating RV from the LV and septum. The weight of these two parts was determined by reassembling the respective slices to obtain Fulton's index (the ratio of RV/LV+S).

**Histological analysis of lungs and heart**

The lungs (the upper lobe of the right lung) and hearts were fixed in 10% formalin (pH 7.4) for 24 hours, embedded with paraffin, sliced serially (4 um), and stained with HE and Masson Trichrome. Histologic images of lungs and heart tissues, including pulmonary small vessels, were captured with an optical microscope and analyzed using image pro plus 6.0. The external diameter (ED), internal diameter (ID), total vascular area (TA), lumen area (LA), wall thickness (WT), wall area (WA), WT% ((ED-ID)/ED × 100%), WA% ((TA-LA)/TA × 100%) of the pulmonary arterioles and the cardiomyocyte cross-sectional area were calculated. Cardiomyocyte cross-sectional area was obtained from cells with nucleuses located in the center of the histologic images. In addition, cardiac fibrosis was evaluated from Masson Trichrome by assessing the blue pixels.

**Immunohistochemistry of lungs and heart**

Paraffin sections of lungs and heart specimens (each thickness is 4 µm) were dewaxed in 100% toluene twice, and then rehydrated by immersing in decreasing ethanol concentration (100%, 95%, 85%, 75%) and in distilled water finally. Endogenous peroxidase activity was blocked with 0.3% (vol/vol) H₂O₂ in methanol for 15 minutes. After three washes with PBS, the sections were then preincubated in 3% (vol/vol) bovine serum albumin in PBS for 30 min, and incubated with polyclonal anti-IL-6 (Bioss Cat# bs-0782R-Biotin, RRID: AB_11085421) or anti-TNF-α (1:100 in PBS, Bioss, China) antibodies overnight at 4°C. The sections were then washed three times with PBS, exposed to biotin-labeled secondary antibodies (Dako, Trappes, France) for 1 hour and then in 3,3’-diaminobenzidine tetrahydrochloride dihydrate (DAB, Sigma, St Louis, MO) for peroxidase staining. Finally, the sections were exposed to hematoxylin for several seconds. After viewed and photographed under an optical microscope, Image Pro Plus 6.0 software was used to select the brownish yellow areas of the immunohistochemical complex in the image, and the average optical density value (IOD) of these areas was measured.

**Measurement of oxidative stress levels**

After tissue homogenization, commercial oxidative stress kits (Nanjing Jiancheng Biotechnology Institute, China) were used to respectively detect the level of MDA and activity of SOD and GSH-Px in the upper lobe of the right lung and RV tissues.

**Western blot assay**

Total protein was separated from the upper lobe of the right lung and RV tissues using the protein extraction kit (Bio-Rad, USA) and the protein concentration was determined using the BCA protein quantitative kit (Beyotime, China). After resolved using SDS-PAGE, protein samples (20-50 µg) were moved to polyvinylidene fluoride (PVDF) membrane (Millipore, USA) and probed with antibodies against p-P65 (Cell Signaling Technology Cat# 3037, RRID: AB_2341216), P65 (Cell Signaling Technology Cat# 3034, RRID:AB_330561), pIκBα (Cell Signaling Technology, USA, 1:1000), ERK1/2 (Cell Signaling Technology Cat# 8993, RRID: AB_2787687), pERK1/2 (Cell Signaling Technology Cat# 9101, RRID:AB_331646), ERK1/2 (Cell Signaling Technology Cat# 9102, RRID:AB_33074), p-P38MAPK (Cell Signaling Technology Cat# 5302, RRID:AB_561213), P38MAPK (Cell Signaling Technology Cat# 9217, RRID:AB_331298), GAPDH (ProteinTech, USA, 1:5000), Tubulin (ProteinTech, USA, 1:5000), and β-actin (ProteinTech, USA, 1:5000), followed by appropriate secondary antibody. All Western blots were repeated at least three times.
Sevoflurane prevents pulmonary arterial hypertension

Am J Transl Res 2021;13(10):11302-11315

Statistical analysis

Statistical analyses were performed with SPSS 23.0. Dates are reported as mean ± SD. P values of <0.05 or <0.01 were considered significant. Normality of data was checked, and either log-transformation or nonparametric testing was performed if data were not normally distributed. The effects of MCT injection compared with control group and the effects of sevoflurane compared with MCT were characterized by Student's t-test. The effects of sevoflurane compared with MCT and control were characterized by a one-way repeated measure ANOVA. The percent RVF between group M and group MS was performed by Kaplan-Meier analysis.

Results

PAH induced by MCT injection in right heart

At the end of the study, i.e., 6 weeks after MCT injection (or 1-2 weeks earlier), most rats in group M presented various clinical signs of RVF such as dyspnea, wheezing, cyanosis of the nose and lips, lethargy, decreased activity, reduced food intake, and erect hair. Some rats in this group also had pericardial and pleural effusions. Figure 1 shows the histologic changes in the hearts of animals from group C and group M. The RV wall was thickened with dilatation. There were no significant differences in the mean heart weight (1034±171 g vs. 1189±150 g, P>0.05) and LV weight (878±144 g vs. 899±153 g, P>0.05) between the two groups, but the mean RV weight in group M was statistically more than that in group C (201±51 g vs. 141±36 g, P<0.05) (Table 1). Fulton's index between the two groups was also significantly different (41.3±7.3 vs. 30.1±8.1, P<0.05) (Table 1). Clearly, RVF developed as a result of MCT injection.

Sevoflurane improved right heart function and prevented progression toward RVF

To investigate whether sevoflurane administration impacts the development of RVF, we administrated sevoflurane via inhalation intermittently for 1 hour twice a week for two weeks after MCT injection and performed serial echocardiography to follow changes in the right heart. We calculated cardiac output to evaluate heart systolic function at the end of experiment. As is shown in Figure 2A, cardiac output was significantly different in group MS in comparison with Group M (70.65±1.33 ml/min vs. 52.35±1.65 ml/min, P<0.05). In addition, survival analysis indicated that sevoflurane could prevent the progression toward RVF in comparison with animals only injected with MCT (Figure 2B, P<0.05).

Figure 2C shows the weekly changes in mean BW (ΔBW) 1, 2, 3, 4, 5 and 6 weeks after MCT injection, and Figure 2D shows the overall changes in BW after the final recordings (ΔBW6) in four groups. The weight of control group and group CS maintained steady growth, whereas in MCT group the weight reduced at week 6 (Figure 2C). MCT injection was associated with a relatively reduced ΔBW6 (89.75±6.86 g vs. 150.85±14.64 g, P<0.05) and animals that inhaled sevoflurane (at MAC 1.5) presented an increased ΔBW6 (113.83±11.53 g vs. 89.75±6.86 g, P<0.05) (Figure 2D).

These data show that sevoflurane can protect right heart from pathologic remodeling, maintain right heart function, and prevent the progression towards RVF during pulmonary hypertension.
Sevoflurane prevents pulmonary arterial hypertension

Echocardiography was performed to determine the structure changes in the RV. Figure 3 shows the echocardiography images of three representative rats from each group. Figure 3A shows the parasternal long axis LV view and it was observed that RV was obviously enlarged, the RV wall was thickened, and the interventricular septum expanded to LV, resulting in compression of the left ventricular cavity. Figure 3B is pulmonic valve flow pulse wave Doppler signal obtained at the parasternal short axis LV view, and the blood flow spectrum of pulmonary arteries in group M showed an asymmetrical inverted triangle, even daggers, with a reduced peak and a significant forward shift. Figure 3C represents pulmonary vascular diameter measurements at the parasternal short axis LV view (long axis pulmonary artery section), and widening and dilation of the RV outflow tract and pulmonary artery were observed. The parameters obtained from echocardiography are presented in Table 2. At MAC 1.5, sevoflurane decreased RVEDD (0.263±0.013 mm vs. 0.331±0.015 mm, P<0.05), RVWTd (0.217±0.006 mm vs. 0.254±0.011 mm, P<0.05), and PAID (0.333±0.009 mm, P<0.01), but increased PV.
Sevoflurane prevents pulmonary arterial hypertension

Group C

Group CS

Group M

Group MS
Sevoflurane prevents pulmonary arterial hypertension

Figure 3. Representative echocardiographic tests graph. A. The parasternal long axis LV view; B. Pulmonic valve flow pulse wave Doppler signal obtained at the parasternal short axis LV view; C. Pulmonary vascular diameter measurements at the parasternal short axis LV view (long axis pulmonary artery section). LA, left atrium; AO, the aorta; PA, pulmonary artery; RT PA, right pulmonary artery; Lt PA, left pulmonary artery.

Table 2. The recordings of echocardiography

<table>
<thead>
<tr>
<th>Variable</th>
<th>Group C</th>
<th>Group CS</th>
<th>Group M</th>
<th>Group MS</th>
</tr>
</thead>
<tbody>
<tr>
<td>RVEDD (mm)</td>
<td>0.213±0.009</td>
<td>0.221±0.011</td>
<td>0.331±0.015*</td>
<td>0.263±0.013**</td>
</tr>
<tr>
<td>RVWTd (mm)</td>
<td>0.116±0.106</td>
<td>0.130±0.017</td>
<td>0.254±0.011*</td>
<td>0.217±0.006**</td>
</tr>
<tr>
<td>IVSd (mm)</td>
<td>0.133±0.006</td>
<td>0.139±0.013</td>
<td>0.175±0.021*</td>
<td>0.162±0.009*</td>
</tr>
<tr>
<td>LVPWd (mm)</td>
<td>0.132±0.003</td>
<td>0.145±0.016</td>
<td>0.162±0.022</td>
<td>0.160±0.007</td>
</tr>
<tr>
<td>PV (m/s)</td>
<td>106.633±2.542</td>
<td>103.301±2.457</td>
<td>57.353±5.379**</td>
<td>80.538±5.446***</td>
</tr>
<tr>
<td>PAID (cm)</td>
<td>0.312±0.002</td>
<td>0.314±0.003</td>
<td>0.355±0.009**</td>
<td>0.333±0.004**</td>
</tr>
</tbody>
</table>

All values are presented as mean ± SD. Group C, n=12; Group CS, n=12; Group M, n=12; Group MS, n=12. *P<0.05 compared with corresponding values in Group C. **P<0.01 compared with corresponding values in Group M. ***P<0.01 compared with corresponding values in Group C. ****P<0.05 compared with corresponding values in Group M. **P<0.01 compared with corresponding values in Group M. RVEDD: the right ventricle end-diastolic dimension; RVWTd: right ventricle wall thickness in diastole; IVSd: intraventricular septum in diastole; LVPWd: LV posterior wall thickness in diastole; PV: the maximal velocity of pulmonic valve; PAID: pulmonary arterial internal dimension.

To gain more insight into the pulmonary artery and RV remodeling at cellular level, HE staining and immunohistochemical analysis of inflammatory factors IL-6 and TNF-α in tissues of lungs and hearts. Since there were no significant differences in the degree of pulmonary vascular remodeling, RV structure and function between group C and CS, we selected rat samples from group C, group M and group MS for subsequent experiments (Figure 5). Exposure to MCT was associated with a rapid rise in lung IL-6 (Figure 5A, 517.359±63.831 vs. 77.715±20.288, P<0.01) and TNF-α (Figure 5B, 567.349±80.223 vs. 70.535±34.267, P<0.01) immunostaining. Cardiac tissue IL-6 (Figure 5C, 896.803±170.864 vs. 74.179±58.081, P<0.01) and TNF-α (Figure 5D, 646.803±83.226 vs. 96.322±53.953, P<0.01) levels were also increased in week 6. In contrast, levels of IL-6 and TNF-α in both lungs (IL-6, Figure 5A, 377.410±69.829 vs. 517.359±63.831, P<0.01; TNF-α, Figure 5B, 477.460±40.387 vs. 567.349±80.223, P<0.01) and hearts (IL-6, Figure 5C, 488.047±86.792 vs. 896.803±170.864, P<0.01; TNF-α, Figure 5D, 421.381±72.452 vs. 646.803±83.226, P<0.01) were significantly lower in rats treated with sevoflurane. These findings suggest that sevoflurane produced anti-inflammatory and anti-oxidative stress effects and maintained RV function, thus preventing the development of RVF during PAH.

Sevoflurane reduced pulmonary and cardiac inflammation

To assess whether the improved RV function, reduced pulmonary vascular and RV remodeling by sevoflurane are related to inhibition of inflammation, we performed immunohistochemical analysis of inflammatory factors IL-6 and TNF-α in tissues of lungs and hearts. Since there were no significant differences in the degree of pulmonary vascular remodeling, RV structure and function between group C and CS, we selected rat samples from group C, group M and group MS for subsequent experiments (Figure 5). Exposure to MCT was associated with a rapid rise in lung IL-6 (Figure 5A, 517.359±63.831 vs. 77.715±20.288, P<0.01) and TNF-α (Figure 5B, 567.349±80.223 vs. 70.535±34.267, P<0.01) immunostaining. Cardiac tissue IL-6 (Figure 5C, 896.803±170.864 vs. 74.179±58.081, P<0.01) and TNF-α (Figure 5D, 646.803±83.226 vs. 96.322±53.953, P<0.01) levels were also increased in week 6. In contrast, levels of IL-6 and TNF-α in both lungs (IL-6, Figure 5A, 377.410±69.829 vs. 517.359±63.831, P<0.01; TNF-α, Figure 5B, 477.460±40.387 vs. 567.349±80.223, P<0.01) and hearts (IL-6, Figure 5C, 488.047±86.792 vs. 896.803±170.864, P<0.01; TNF-α, Figure 5D, 421.381±72.452 vs. 646.803±83.226, P<0.01) were significantly lower in rats treated with sevoflurane. These findings suggest that sevoflurane produced anti-inflammatory and anti-oxidative stress effects and maintained RV function, thus preventing the development of RVF during PAH.
Sevoflurane prevents pulmonary arterial hypertension

Sevoflurane inhibition NF-κB and MAPK pathways

As is shown in Figure 6, p-P65/P65, pIkBα/IκBα, pERK1/2/ERK1/2 and p-P38MAPK/P38MAPK expression levels were significantly higher in group M than those in group C ($P<0.01$), but were significantly lower in the MS group than those in the M group ($P<0.01$), indicating that NF-κB and MAPK pathways were involved in sevoflurane’s protective effect on pulmonary vascular remodeling and RV dysfunction in PAH in Rats.

Discussion

RV function in pulmonary hypertension and the model of PAH

In the recent years, the importance of RV has been widely recognized, but it still remains
Sevoflurane prevents pulmonary arterial hypertension

understudied compared with the LV. There are many differences between RV and LV, so knowledge from the LV cannot be directly applied to the RV. In pulmonary hypertension, RV adapts to the increasing afterload by enhancing contractility to maintain the blood flow. The gradual dysfunction and failure of the RV remained as the main contributors to mortality and disability for patients with pulmonary hypertension. Moreover, RV dysfunction is a better important independent risk factor for predicting the prognosis of patients than pulmonary vascular resistance. A multicenter clinical study showed that RVF accounts for 70% cause of the death in patients with PAH [11]. Taken together, it is crucial to pay attention to and protect the RV function of patients in the perioperative period.

Figure 5. Immunolocalization of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) and oxidative stress levels (E-G) in lungs and heart from rats (original magnification 100). IL-6 levels (A) and TNF-α levels (B) in lung tissue, IL-6 (C) and TNF-α (D) levels in cardiac tissue. MDA level (E), SOD (F) and GSH-Px (G) activity in lung and cardiac tissue. Each value is semiquantitatively analyzed. *P<0.05 compared with corresponding values in Group C; #P<0.05 compared with corresponding values in Group M.
We elected MCT 60 mg/kg to be injected intra-peritoneally to establish the model of pulmonary vascular remodeling and RVH. MCT is a toxic pyrrolizidine alkaloid found in the plant Crotalaria spectabilis, which can cause acute and subacute damages of the peripheral vasculature of lung through early adventitial inflammation followed by progressive smooth muscle hypertrophy in the media [12]. In the present study, after MCT injection, RV wall thickness and weight were both increased (Figures 1, 3; Tables 1, 2) and cardiac output was decreased (Figure 2A). These results confirmed that the RV adapted to the increased pulmonary arterial pressure through concentric hypertrophy, however, because RV systolic function measured by cardiac output was still impaired, this adaptation can be considered as insufficient and final result in RVF (Figure 2B).

**Inflammation, pulmonary vascular remodeling and RVH**

Previous studies have demonstrated the important role of inflammation in pathogenesis of PAH, and the involvement of IL-6 and THF-α in the inflammation pathway has been described. In animal model of hypoxic pulmonary hypertension, levels of 48 mRNAs associated with inflammation were upregulated [13]. Bone morphogenetic protein receptor 2 (BMRP2) [14], NF-κB [15], transforming growth factor beta (TGF-β) signaling pathways changes had also been linked to rat or mice models of PAH and had interrelation with each other. Using IL-6−/− mice, Laurent Savale et al. [16] found that the numbers of muscular pulmonary vessels and inflammation cells recruitment were reduced after 2 weeks of hypoxic treatment than in IL-6+/+ mice, suggesting the specific role of IL-6 in attenuating the development of PAH in mice. In addition, increased levels of proinflammatory factors like IL-6, Tnf, Ccl-2 have been reported in PAH patients [17, 18]. Furthermore, these elevated levels of inflammation cytokines could predict survival in patients with PAH [19], and were even superior to traditional prognostic markers, such as 6-minute walking and hemodynamics. In human RVF, inflammatory pathway had been demonstrated to be more important in RV tissue [20]. Circulating dendritic cells as well as tissue resident immune cells could reflect right heart function [21]. More importantly, inflammation was even involved in PAH with left heart failure [22]. In the present study, we provided direct evidence that local inflammation activity of the lungs and heart in experimental PAH is significant (Figures 4A, 5). In addition, we demonstrated that reduced inflammation is associated with reduced pulmonary vascular remodeling and RVH. These findings suggest a crucial pathophysiological role of inflammation in PAH.
Sevoflurane prevents pulmonary arterial hypertension

Previous studies in animal models of IR injury have described the beneficial effects of sevoflurane and inflammation response in this process. However, the anti-inflammation action of sevoflurane in experimental PAH is still unknown. In the current study, we offer evidence that sevoflurane inhaled at MAC 1.5 reduced lungs and heart local proinflammatory markers IL-6 and TNF-α production (Figure 5), resulting in protection of the RV during PAH, and this effect may be associated with NF-κB and MAPK pathways (Figure 6). Sevoflurane administration was associated with decreased small vessel intimal hyperplasia and luminal narrowing, along with less congestion and structure alterations, as observed in HE staining (Figure 4A).

The concentration of the inhalation anesthetic used is discrepant in different studies. It can be adjusted to the animal's response to deep paw pinch (animals were further hyperventilated to avoid spontaneous breathing during recordings) or obey strictly imposed MAC as in the present study. However, different experimental protocol may influence the underlying sympathetic tone between studies, a consequence that is in connection with cardiovascular changes in PAH. In previous studies on sevoflurane pretreatment or postconditioning in myocardial IR injury either in vitro or in vivo, researchers have demonstrated that 2.4-3.6 vol% (equal to 1-1.5 MAC) sevoflurane [23-26] could produce anti-ischemia effects. Also, in the preliminary experiment, we had confirmed that sevoflurane at 1.5 MAC would not prevent the occurrence of spontaneous breathing of rats, and this is consistent with the clinical effective dose of sevoflurane [27].

Inflammation is considered to be a crucial mediator of complications of cardiac surgery. And sevoflurane has been proved to have the ability to quench inflammation. Previous studies have demonstrated reduced plasma or alveolar levels of TNF-α, IL-1β, IL-6, IL-8, and INF-γ and increased levels of IL-10 in animal models of lung injury from various causes [28-31] and patients with acute respiratory distress syndrome (ARDS) [32] when administrated with sevoflurane. Other preclinical studies, such as spinal cord IR, murine allergic airway inflammation, also confirm this potential of sevoflurane on pro-inflammation and anti-inflammation factors. Of interest, new applications of sevoflurane have been tried in cardiac surgery and allergic airway inflammation to achieve better anti-inflammation effect, such as intramyocardial delivery, repeated inhalation. More importantly, even sevoflurane metabolite hexafluoro-2-propanol also has a potential of immunomodulatory effect by reducing IL-6 expression in a rat model of endotoxaemia. The level of these cytokines is closely related to the prognosis of patients. And the anti-inflammation effect of sevoflurane is mainly regulated via inhibition of the NF-κB, TLR4, NLRP3, or other signaling pathways.

The physiological function of NF-κB has been widely studied. It can regulate the expression of various growth factors (such as VEGF), inhibit the apoptosis of PASMOCs, regulate the expression of IL-6 and other inflammatory factors, and interfere with immune regulation, making it a research hotspot in the pathophysiological mechanism of pulmonary vascular remodeling in PAH. The activation of NF-κB was found in the lung tissue of PAH patients and in the animal PAH models induced by SU5416, chronic hypoxia and MCT, and was found throughout the whole PAH disease process. In the present study, MCT treatment induced up-regulation of p-P65 and pIkBα, indicating the involvement of NF-κB in PAH and RVH, and sevoflurane could regulate the expression of key NF-κB protein to reduce the pathological changes of RV (Figure 6). Notably, inhibition of NF-κB did not reduce IL-6 levels in PAH lung tissue, suggesting that there are other signaling pathways or molecules that stimulate IL-6 secretion in advanced PAH [33].

MAPK pathway is another signal pathway closely related to PAH process, which is involved in PAH initiation and maintenance. It is not only associated with endothelial dysfunction and excessive cell proliferation, but also with RVH and RV dysfunction in PAH. In addition, MAPK can also induce inflammatory cascades and thus participate in PAH processes. MAPK can participate in the process of autophagy, leading to the degradation of macromolecules, apoptosis, and increased production of macrophage colony stimulating factor (GM-CSF), induce macrophage aggregation, and aggra-
Sevoflurane prevents pulmonary arterial hypertension

vate PAH in human and experimental animals. In this experiment, MCT treatment for 6 weeks caused the up-regulation of p-ERK1/2 and p-P38 protein levels, indicating that MAPK is involved in the process of PAH and RVH, while sevofluran can regulate the expression of key MAPK proteins to reduce RV changes (Figure 6).

Limitation

We used a rat model of PAH induced by MCT intraperitoneal injection, a condition known to be characterized by increased inflammation, to assess the effects of sevofluran. However, the animal model may have some differences from clinical patients with PAH, so more clinical studies may need to be performed to further identify whether cardioprotective properties of this volatile anesthetic are identical to what can be observed in animal model.

Evaluation of RV function is challenging. It can be directly assessed by right heart catheterization, which has a significant effect on the diagnosis, prognostic evaluation, and decision-making of PAH patients [34]. Clearly, RV catheterization with pressure-volume analyses would be valuable to better understand the load-independent parameter of RV function, like RV contractility and diastolic stiffness. And LV catheterization with pressure-volume analyses is helpful to understand how changes of RV affect the LV contractility. However, considering the pulmonary artery catheter is invasive and relative insecurity, and at the same time, it is not suitable for serially monitoring cardiac performance, we chose echocardiography to map the progression of cardiac dysfunction and structure changes. Studies had shown that it has obvious correlation with invasive hemodynamic examination and can replace catheterization [35, 36]. Novel technologies over the past 3 decades, such as speckle-tracking imaging-based regional LV analysis, perfusion imaging, fetal echocardiography, and myocardial deformation imaging etc., enable ultrasound echocardiography to be a powerful tool to translate small animals data to enhanced clinical understanding and treatment of cardiovascular diseases [37].

Conclusion

In this study, we demonstrated that reduced local inflammatory activity is associated with improved right heart function, absence of RVF, and reduced pulmonary vascular pathologic remodeling in experimental PAH. The beneficial effects of sevofluran were associated with reduced IL-6 and TNF-α expressions and inhibition of NF-κB and MAPK. Our findings revealed cardioprotective properties of this volatile anesthetic and encourage further experimental and clinical investigations to study the molecular mechanism underlying this process.

Acknowledgements

This study was supported by the Tianjin health science and technology project self-raised project (Project number: ZC20007).

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Jiange Han, Department of Anesthesiology, Tianjin Chest Hospital, No. 261 South Taierzhuang Road, Tianjin 300222, China. Tel: +86-13821001156; E-mail: hanjiange@163.com; Dr. Jie Geng, Department of Cardiology, Tianjin Chest Hospital, No. 261 South Taierzhuang Road, Tianjin 300222, China. Tel: +86-022-8818-5157; E-mail: tjkk178@163.com

References


Sevoflurane prevents pulmonary arterial hypertension


Sevoflurane prevents pulmonary arterial hypertension


